Kwasnik v. Oxford Health Insurance, Inc.

Background

Fiana Kwasnik sued Oxford Health Insurance, Inc. under Section 502(a)(1)(B) of the Employee Retirement Income Security Act of 1974, commonly called ERISA. She alleged that Oxford wrongfully denied benefits under a group medical plan provided through her employer. The parties filed cross-motions for summary judgment, asking the court to decide the case without a trial because they claimed there was no genuine dispute about any important fact.

Kwasnik sought coverage for several infertility-related services: fertilization of oocytes retrieved and frozen in 2017, a new oocyte retrieval in 2021, fertilization of the 2017 and 2021 oocytes by intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing for aneuploidy (PGT-A) of resulting embryos. The plan covered medically necessary services and provided coverage for three lifetime in-vitro fertilization cycles, subject to the plan’s terms.

Oxford denied coverage for a new in-vitro fertilization cycle because Kwasnik had nine oocytes frozen in 2017 that were available for use. Oxford also denied coverage for ICSI and PGT-A testing on medical-necessity grounds. During the review process, Oxford approved coverage for ICSI after an independent review, but the New York State external review assigned to Island Peer Review Organization later determined that ICSI was not medically necessary. The opinion treats that external determination as binding under the plan. Oxford also approved certain services involving thawing and fertilizing the 2017 oocytes and transferring resulting embryos.

Standard of review

The plan gave Oxford discretionary authority to administer benefits. The court therefore reviewed Oxford’s decisions under the arbitrary-and-capricious standard rather than independently deciding eligibility from the beginning. Under that deferential standard, a denial is upheld if it has a reason and is supported by substantial evidence.

Kwasnik argued that the court instead had to conduct a de novo review, meaning an independent review without deference to Oxford, because Oxford allegedly violated federal rules governing ERISA claims procedures. She argued that Oxford failed to provide her claim file, failed to consider information she submitted, and gave improper deference to earlier benefit decisions.

The court rejected those arguments. It found no evidence that Kwasnik requested her claim file in the administrative record. It also concluded that the record showed Oxford considered both the plan and New York’s infertility-coverage law. Finally, the court found no evidence that the reviewers improperly deferred to earlier decisions or that the same reviewers, or their subordinates, improperly handled the appeals. Because Kwasnik did not establish a violation of the claims-procedure rules, the court applied the arbitrary-and-capricious standard.

Merits

The court held that Oxford’s denial of coverage for a new in-vitro fertilization cycle was reasonable. Oxford’s guidelines stated that a fresh oocyte retrieval was not indicated when previously frozen oocytes or embryos were available. The court concluded that Oxford did not count the 2017 oocytes as a prior treatment cycle under New York’s three-cycle requirement. Instead, Oxford denied the requested new cycle because it was not medically necessary while the frozen oocytes remained available.

The court also upheld the denial of PGT-A testing. Oxford’s plan and guidelines treated that testing as unproven and not medically necessary absent evidence that a parent had a genetic condition or carried an abnormal gene or chromosomal condition associated with a recognized inherited disorder. The court found that the medical record supported Oxford’s conclusion that those circumstances were not shown.

The court upheld the denial of ICSI as well. The external reviewer concluded that ICSI was not medically necessary because, although it might increase fertilization rates in some circumstances, it had not been shown to improve live-birth outcomes in the circumstances presented. The court acknowledged that Oxford had earlier approved ICSI after another independent review, but it concluded that the later external-review determination was binding under the plan.

The court rejected Kwasnik’s arguments that Oxford ignored her treating physician, applied its guidelines inconsistently, or improperly treated the 2017 oocytes as available. The court stated that Oxford was not required to defer to the treating physician’s opinion and that reasonable disagreement about medical necessity did not make Oxford’s decision arbitrary or capricious. It also found no evidence that a conflict of interest affected Oxford’s decisions.

Disposition

Judge Valerie Caproni granted Oxford’s motion for summary judgment and denied Kwasnik’s motion for summary judgment. The Clerk was directed to close the motions at docket entries 99 and 105 and terminate the case.